Compare CIX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIX | RCKT |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.5M | 340.9M |
| IPO Year | 1998 | N/A |
| Metric | CIX | RCKT |
|---|---|---|
| Price | $23.51 | $3.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.12 |
| AVG Volume (30 Days) | 14.4K | ★ 2.0M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.77% | N/A |
| EPS Growth | ★ 2.86 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $159,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.36 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $17.89 | $2.19 |
| 52 Week High | $32.30 | $13.35 |
| Indicator | CIX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 46.08 |
| Support Level | $20.29 | $3.30 |
| Resistance Level | $24.62 | $3.57 |
| Average True Range (ATR) | 0.92 | 0.18 |
| MACD | 0.24 | -0.01 |
| Stochastic Oscillator | 54.04 | 22.81 |
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's operating segment includes Security Products and Marine Components. The company generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Its geographical segments are the United States, Canada, Mexico, and others, of which the United States accounts for the vast majority of revenue.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.